The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation-Reference-Cited by-同舟云学术

The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation

Published:2015-10-07 Issue:35 Volume:6 Page:37871-37894
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Zhao Wuli¹,Jiang Guohua²,Bi Chongwen¹,Li Yangbiao¹,Liu Jingbo³,Ye Cheng¹,He Hongwei¹,Li Liang¹,Song Danqing¹,Shao Rongguang¹

Affiliation:

1. Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

2. Analysis and Testing Center, Beijing Normal University, Beijing, China

3. China Meitan General Hospital, Beijing, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Indolo[3,2-c]isoquinoline Derivatives as Novel Top1/2 Dual Inhibitors with Orally Efficacious Antitumor Activity and Low Toxicity;Journal of Medicinal Chemistry;2024-08-06

2. A review on potential therapeutic targets for the treatment of leishmaniasis;Parasitology International;2024-06

3. Design, synthesis and molecular modeling studies of thiosemicarbazide & thiazolyl-hydrazone derivatives as potential anticancer agents and topoisomerase inhibitors;Journal of Molecular Structure;2024-04

4. Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer;European Journal of Medicinal Chemistry;2022-07

5. Design, synthesis and anti-hepatocellular carcinoma activity of 3-arylisoquinoline alkaloids;European Journal of Medicinal Chemistry;2022-01